Skip to main content
    O

    Omeros Corporation (OMER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.68
    -0.81 (-4.63%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Omeros Corporation (OMER) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Omeros (OMER) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Omeros reported EPS of $0.02, above the -$0.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +22.84%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.07
    Range-$0.02 - $0.14
    5 analysts
    Revenue Consensus
    $52.85M
    Range$33.12M - $75.64M
    5 analysts

    Next Report

    OMER has an expected report date of Mar 29, 2027.

    OMER Earnings Call

    The latest OMER earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OMER beat 21, missed 18 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 459.65% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026$0.02-$0.27-$0.39 - -$0.27+107.41%BeatN/A21 up, 0 downAug 13, 2026$28.53M
    Mar 31, 2026$0.57-$0.39-$0.40 - -$0.38+246.15%BeatN/A31 up, 0 downMay 13, 2026$9.89M
    Dec 31, 2025-$0.55-$0.52-$0.62 - $2.24-5.04%MissN/A31 up, 0 downMar 31, 2026N/A
    Sep 30, 2025-$0.32-$0.48-$0.58 - -$0.37+33.33%BeatN/A41 up, 3 downNov 13, 2025N/A
    Jun 30, 2025-$0.53-$0.55-$0.74 - -$0.44+3.64%BeatN/A40 up, 1 downAug 14, 2025N/A
    Mar 31, 2025-$0.65-$0.58-$0.74 - -$0.53-12.07%MissN/A30 up, 0 downMay 15, 2025N/A
    Dec 31, 2024-$0.55-$0.71-$1.07 - -$0.48+22.54%BeatN/A31 up, 1 downMar 31, 2025N/A
    Sep 30, 2024-$0.64-$0.77-$0.77 - -$0.64+16.88%BeatN/A20 up, 0 downNov 13, 2024N/A
    Jun 30, 2024-$1.12-$1.01-$1.51 - -$0.94-10.89%MissN/A30 up, 1 downAug 7, 2024N/A
    Mar 31, 2024-$0.75-$0.63N/A-19.05%MissN/A30 up, 0 downApr 1, 2024N/A
    Dec 31, 2023-$0.15-$0.55-$0.65 - -$0.46+72.73%Beat-107.3%20 up, 0 downMar 26, 2024N/A
    Sep 30, 2023-$0.82-$0.66-$0.68 - -$0.56-24.24%MissN/A31 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.70-$0.53N/A-32.08%MissN/A30 up, 0 downAug 9, 2023N/A
    Mar 31, 2023-$0.63-$0.57-$0.72 - -$0.41-10.53%MissN/A40 up, 0 downMay 9, 2023N/A
    Dec 31, 2022$2.05-$0.57-$0.64 - -$0.47+459.65%BeatN/A51 up, 0 downMar 13, 2023N/A
    Sep 30, 2022-$0.87-$0.58N/A-50.00%MissN/A40 up, 0 downNov 9, 2022N/A
    Jun 30, 2022-$0.66-$0.66N/A0.00%In lineN/AN/A0 up, 0 downAug 9, 2022N/A
    Mar 31, 2022-$0.53-$0.69-$0.78 - -$0.61+23.19%BeatN/A30 up, 1 downMay 10, 2022N/A
    Dec 31, 2021-$0.37-$0.36-$0.48 - -$0.30-2.78%MissN/A50 up, 0 downMar 1, 2022N/A
    Sep 30, 2021-$0.36-$0.47-$0.51 - -$0.45+23.40%BeatN/A71 up, 0 downNov 9, 2021N/A
    Jun 30, 2021-$0.46-$0.55-$0.75 - -$0.44+16.36%BeatN/A8N/AAug 9, 2021N/A
    Mar 31, 2021-$0.57-$0.51-$0.80 - -$0.37-11.76%MissN/A6N/AMay 10, 2021N/A
    Dec 31, 2020-$0.60-$0.69-$0.83 - -$0.44+13.04%BeatN/A7N/AMar 1, 2021N/A
    Sep 30, 2020-$0.34-$0.49-$1.31 - -$0.37+30.61%BeatN/A7N/ANov 9, 2020$26.11M
    Jun 30, 2020-$0.61-$0.59-$0.93 - -$0.38-3.39%MissN/A6N/AAug 10, 2020$13.53M
    Mar 31, 2020-$0.53-$0.34-$0.44 - -$0.23-55.88%MissN/A5N/AMay 11, 2020$23.54M
    Dec 31, 2019-$0.58-$0.50-$0.98 - -$0.24-16.00%MissN/A6N/AMar 2, 2020N/A
    Sep 30, 2019-$0.33-$0.41-$0.57 - -$0.26+19.51%BeatN/A6N/ANov 12, 2019$29.86M
    Jun 30, 2019-$0.29-$0.44-$0.58 - -$0.37+34.09%BeatN/A6N/AAug 8, 2019$26.75M
    Mar 31, 2019-$0.50-$0.47N/A-6.38%MissN/A4N/AMay 9, 2019$21.78M
    Dec 31, 2018-$0.21-$0.81-$1.10 - -$0.60+74.07%BeatN/A5N/AMar 1, 2019$22.02M
    Sep 30, 2018-$0.81-$0.71-$1.03 - -$0.68-14.08%MissN/A5N/ANov 8, 2018$4.61M
    Jun 30, 2018-$0.70-$0.62-$0.90 - -$0.52-12.90%MissN/A6N/AAug 9, 2018$1.66M
    Mar 31, 2018-$0.62-$0.59-$0.64 - -$0.50-5.08%MissN/A4N/AMay 10, 2018$1.59M
    Dec 31, 2017-$0.34-$0.17-$0.30 - -$0.06-100.00%MissN/A5N/AMar 1, 2018$13.76M
    Sep 30, 2017-$0.16-$0.34-$0.42 - -$0.26+52.94%BeatN/A5N/ANov 9, 2017$21.66M
    Jun 30, 2017-$0.33-$0.37-$0.50 - -$0.29+10.81%BeatN/A6N/AAug 8, 2017$17.15M
    Mar 31, 2017-$0.34-$0.35N/A+2.86%BeatN/AN/AN/AMay 10, 2017$12.26M
    Dec 31, 2016-$0.45-$0.56N/A+19.64%BeatN/AN/AN/AMar 16, 2017$12.90M
    Sep 30, 2016-$0.34-$0.36N/A+5.56%BeatN/AN/AN/ANov 9, 2016$11.29M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after -$3.06 the year before. It was -$1.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.05N/A
    Dec 31, 2024-$3.06N/A
    Dec 31, 2023-$2.30N/A
    Dec 31, 2022-$0.01N/A
    Dec 31, 2021-$1.76N/A
    Dec 31, 2020-$2.08N/A
    Dec 31, 2019-$1.70N/A
    Dec 31, 2018-$2.34N/A
    Dec 31, 2017-$1.17N/A
    Dec 31, 2016-$1.65N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,700 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20265,73210
    2026Q1Mar 31, 20264,86010
    2025Q4Dec 31, 20255,5199
    2025Q3Sep 30, 20255,19910
    2025Q2Jun 30, 20254,0469
    2025Q1Mar 31, 20253,9786
    2024Q4Dec 31, 20247,07411
    2024Q3Sep 30, 20245,3319

    2026Q2 Earnings Call

    Opening remarks

    Jennifer Williams Investor Relations Please go ahead.

    Gregory A. Demopulos Chairman and CEO Thank you, and good afternoon, everyone. Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the risk factors in our quarterly report on Form 10-Q filed today with the SEC as well as our most recent annual report on Form 10-K. Today's call also will include certain non-GAAP financial measures. A reconciliation of these measures to the corresponding GAAP measures is included in Omeros' earnings release issued earlier today available on the Investor Relations page of our website and furnished with the form 8-K we filed today with the SEC. With that, I will turn the call over to Dr. Gregory Demopulos, Chairman and CEO of Omeros. Thank you, Jennifer, and good afternoon, everyone. Joining me today are David J. Borges, our chief accounting officer, Dr. Kathy Melfi, our chief regulatory officer, Dr. Steve Whitaker, vice president of clinical, and David W. Ghesquiere, our chief commercial officer. Promoted from within the company, David was recently appointed as our chief commercial officer, and let me tell you a bit more about him. David joined Omeros six years ago as our vice president of sales and market development, bringing more than 25 years of industry experience, including sales and marketing leadership roles at Amgen, Spectrum Pharmaceuticals, and Jazz Pharmaceuticals, where he led the global launch of defibrotide. David largely built our commercial team and was instrumental in designing and executing the Yartemlia launch. I have long believed that his background, capabilities, and achievements are ideally suited to Omeros' current and future objectives. Under his leadership, our commercial team is driving Yartemlia toward becoming the standard of care for TA-TMA, and preparing for its expansion into a broad range of MASP-2-driven indications. Beyond that, David's track record of driving growth across oncology, rare disease, and specialty biopharma products will serve Omeros well. Before I turn to the financial details, let me highlight three points. First, Yartemlia generated $32.2 million in gross sales in its first full quarter on the market. Second, operations generated $4.1 million of positive cash flow during the quarter. And third, we meaningfully strengthened our capital structure through our share and note repurchases. So I will now begin with an overview of our second quarter operations and financial results, followed by program updates. David will then review the financials in more detail, after which we will open the call for questions.

    Frequently Asked Questions About OMER

    When is Omeros's next earnings date?

    Omeros's next earnings report is expected for Mar 29, 2027.

    Did OMER beat earnings estimates last quarter?

    Yes. Omeros reported EPS of $0.02 for the quarter ended Jun 30, 2026, above the -$0.27 estimate, a 107.41% surprise.

    What EPS do analysts expect from OMER next quarter?

    The consensus EPS estimate for Omeros for the quarter ending Dec 31, 2026 is $0.07 from 5 analysts, with estimates from -$0.02 to $0.14.

    How often does OMER beat earnings estimates?

    Omeros beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +51.61%.